Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 3/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.36 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6669412 | 0.86 | MGLL (0.43) | CNR1CNR2MGLLUSP30MEN1 | |
| SCHEMBL6670108 | 0.85 | CNR1 (0.39) | CNR1CNR2MGLLSTSUSP30 | |
| SCHEMBL3080435 | 0.82 | CNR1 (0.42) | CNR1CNR2STSUSP30PTPN2 | |
| SCHEMBL3080431 | 0.82 | CNR1 (0.42) | CNR1CNR2STSUSP30PTPN2 | |
| SCHEMBL6667389 | 0.82 | USP30 (0.40) | CNR1CNR2STSUSP30PAK1 | |
| SCHEMBL6671435 | 0.81 | CNR1 (0.38) | CNR1CNR2MGLLSTSPAK1 | |
| SCHEMBL3072600 | 0.81 | CNR1 (0.42) | CNR1CNR2STSUSP30PTPN2 | |
| SCHEMBL3072601 | 0.81 | CNR1 (0.42) | CNR1CNR2STSUSP30PTPN2 | |
| SCHEMBL6670724 | 0.81 | USP30 (0.42) | MGLLUSP30DPP4 | |
| SCHEMBL6672883 | 0.80 | MGLL (0.42) | MGLLUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214815-A1 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY | 2004-10-28 | — | — | US | disclosed |
| US-6762191-B2 | TREATING DISEASES FOR MODULATING OF 5-HT ACTIVITY, CENTRAL NERVOUS SYSTEM DISORDERS, ANXIETY, OBESITY, DEPRESSION, OR A STRESS-RELATED DISEASE | PHARMACIA & UPJOHN COMPANY | 2004-07-13 | — | — | US | disclosed |
| EP-1404679-A2 | (HETERO)ARYL SUBSTITUTED BENZOFURANS AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1316542-A1 | 3-AMINO-1-INDANOLE, METHOD OF SYNTHESIZING THE SAME AND METHOD OF OPTICAL RESOLUTION | Daicel Chemical Industries, Ltd. (JP) | 2003-06-04 | — | — | EP | disclosed |
| US-20030050304-A1 | Therapeutic compounds | PHARMACIA & UPJOHN COMPANY | 2003-03-13 | — | — | US | disclosed |
| WO-2003004501-A2 | (HETERO) ARYL SUBSTITUTED BENZOFURANS AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-01-16 | — | — | WO | disclosed |
| CN-1388802-A | 3-amino-1-indanol, synthesis method thereof and resolution of enantiomer | DAICEL CHEM (JP) | 2003-01-01 | — | — | CN | disclosed |
| US-20020177736-A1 | 3-AMINO-1-INDANOLE, METHOD OF SYNTHESIZING THE SAME AND METHOD OF OPTICAL RESOLUTION | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-28 | — | — | US | disclosed |
| US-6479702-B1 | 3-amino-1-indanole, method of synthesizing the same and method of optical resolution | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214815-A1 | Therapeutic compounds | HTR5A, HTR6, HTR1A | CNR1 36/4885CNR2 77/4885MGLL 3067/4885 |
| US-20030050304-A1 | Therapeutic compounds | HTR5A, HTR6, HTR1A | CNR1 36/4885CNR2 77/4885MGLL 3067/4885 |
| US-20020177736-A1 | 3-AMINO-1-INDANOLE, METHOD OF SYNTHESIZING THE SAME AND METHOD OF OPTICAL RESOLUTION | CYP51A1, IDO1, CYP8B1 | CNR1 408/4885CNR2 495/4885MGLL 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.